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Abstract
Purpose The SEOM Future Plan is aimed at identifying
the main challenges, trends and needs of the medical
oncology speciality over the next years, including potential
oncologist workforce shortages, and proposing recom-
mendations to overcome them.
Methods The estimations of the required medical oncolo-
gists workforce are based on an updated Medical Oncolo-
gist Register in Spain, Medical Oncology Departments
activity data, dedication times and projected cancer inci-
dence. Challenges, needs and future recommendations
were drawn from an opinion survey and an advisory board.
Results A shortage of 211 FTE medical oncologist spe-
cialists has been established. To maintain an optimal ratio
of 158 new cases/FTE, medical oncology workforce should
reach 1881 FTE by 2035.
Conclusions Main recommendations to face the growing
demand and complexity of oncology services include a
yearly growth of 2.5% of medical oncologist’s workforce
until 2035, and development and application of more
accurate quality indicators for cancer care and health out-
comes measure.
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Introduction
Advances in Medical Oncology, including earlier and more
accurate diagnosis, and the discovery of more effective
therapies, are contributing to improve survival rates in
cancer patients and increase the number of long-term sur-
vivors [1]. Nevertheless, cancer is still one of the main
concerns in Spain, as it is the leading cause of death in men
and the second leading cause of death in women [2] as well
as the primary cause of potential years of life lost (PYLL)
[3]. In addition, the incidence of cancer in Spain continues
to increase [1], due in part, to the ageing of the population,
environmental factors and certain life styles in society
today. The Globocan 2012 study predicts an increase of
39% in the incidence of cancer in Spain within the next
20 years, from around 227,000 new cases per year in 2015,
to more than 315,000 in 2035 [4].
The increase of the incidence, the decrease of mortality
rates, and the ageing of population, are causing an increase
in the number of potential cancer patients who will demand
treatment services at Medical Oncology Departments. This
increase in demand will be accompanied by a more com-
plex management, due both to the increase in the number
of complex patients (polymedicated patients, with multiple
pathologies or patients receiving several lines of
chemotherapy as the main factors), and to the continuous
increase of the number of drugs and indications approved
for the treatment of cancer. There are currently more than
2000 drugs in development in the area of oncology, most
aimed at the treatment of tumours in advanced stage or
metastasis [5]. During the period of 2014 to May 2015
along, the Spanish Agency of Medicines and Medical
Devices (AEMPS) approved 16 new indications in the area
of cancer (either new drugs or extension of indication of
already approved drugs) [6].
On the other hand, the significant progress in the field of
human genomics has allowed the rapid advance in the
understanding of tumour biology. Many new drugs act on
molecular targets or signalling paths that correspond to
specific genome alterations, which achieves more focused
and effective anti-tumour activity. This knowledge is
allowing the advance in the application of a ‘‘biomarker
conducted’’ oncologic medicine or ‘‘precision medicine’’.
[7] The number of the so-called ‘‘accompanying diagnos-
tics’’ [genetic analysis, detection of protein or metabolite
levels, etc., according to the Food and Drug Administration
(FDA)] is increasing. Although most of these tests are rec-
ommended by the FDA and the European Medicines Agency
(EMA), clearer evidence on their clinical usefulness must
still be obtained to facilitate their implantation [8].
Within this context of changes, the Spanish Society of
Medical Oncology (SEOM) has considered the need of a
study compiling the main future challenges of the spe-
ciality and a proposal of recommendations to respond to
them with the maximum guarantee of quality in healthcare
delivery and equity of access based on the best available
evidence.
To adequately respond to the challenges to the special-
ity, it is essential to monitor potential medical oncology
workforce shortages. Different studies conducted by the
Ministry of Health, Social Services and Equality have
periodically registered the number of professionals and
have reported estimates of future needs [9]. The enactment
of Royal Decree 640/2014, of the 25th of July, regulating
the creation of the National Register of Health Profes-
sionals, started an important initiative that will be useful
for planning the needs of qualified health professionals, as
well as for coordinating public health Human Resources
policies. However, in view of the lack of updated data on
medical oncology specialists in Spain included in the
available european study [10], and in expectation of
knowing the results of the Register of Health Professionals,
the Project Medical Oncology Future Plan, has produced an
updated Register of Medical Oncologists (MO), which will
serve as the basis for the estimation of future needs.
In addition to the workforce study, the objective of the
study was to identify medical oncologists perception about
the changes that are having impact in their daily practice
and the main challenges and future needs of the speciality.
With that purpose, an online survey was used as the basis
by an Advisory Board for the issuing of recommendations
on the most effective actions to be carried out.
Materials and methods
Register of Medical Oncologists
A register of Medical Oncology Departments, including the
number of medical oncologists in public and private hos-
pitals in Spain in 2014 was prepared. Requests for infor-
mation were sent to Directorates General for Human
Resources of the Regions’ Health Departments, Human
Resources Departments of the main private hospitals and
Hospital Groups or their equivalents. Information was
collected through an electronic survey. In private hospitals,
information about professionals working simultaneously in
private and public sectors was collected to avoid duplica-
tion of data.
Information was collected from 202 public and private
centres. Complete information was obtained from 67% of
medical oncologists registered in public centres and from
61% of oncologists registered in private centres. The data
corresponding to these centres was extrapolated to the
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100% of the Register of Medical Oncologists, in cases for
which detailed information was not available.
The number of medical oncologists was converted to
full time equivalent (FTE), considering part-time contracts,
deducting 10% of the correspondent time for women, due
to the higher probability of leaves or early departure from
the labour market (using estimates from previous studies).
[9].
Estimate of available professionals in the labour
market (offer) according to entry and exit
With the aim of estimating the number of specialists who
will make up the medical oncology workforce in our
country with a time horizon to 2035, a predictive model
was designed based on specialist replacement according to
the entries (number of trained specialists) and exits (pro-
fessionals who exit the healthcare delivery labour market
for different reasons). The model applied made it possible
to quantify the number of specialists in Medical Oncology
with care delivery tasks, who will make up the Medical
Oncology workforce within the next years, and who could
be potentially available to meet healthcare delivery needs.
To estimate the number of entries into the labour mar-
ket, the average of Resident Medical Intern (MIR)-resident
doctor positions published in the Spanish Official Bulletin
during the last 5 years was considered (112 positions per
year), and this number was considered constant [11].
The following aspects were considered to estimate the
number of exits from the labour market: (1) the percentage
of trained specialists who work in sectors other than care
delivery (research, management, pharmaceutical industry,
etc.). This percentage was estimated at 4% based on pre-
vious studies [9]; (2) the percentage of interns’ re-circu-
lation (Medical Oncologists who have finished their
residency and apply for a new speciality, estimated at 10%
based on previous studies [9]), (3) the percentage of interns
trained in our country who work abroad after finishing their
internships (estimated at 2% of the total of Medical
Oncology interns [9]) and (4) the percentage of retirements.
To estimate the number of retirements within the time
frame of the study, the most probable age of retirement
considered was 65 years old, although it was considered
that 10% of professionals would continue working until the
age of 67.
Estimation of the number of medical oncologists
needed related to workloads
For the estimation of the number of specialists required to
fulfil the present and future workloads, the model used
was taken from the First White Book of Medical
Oncology in Spain [12]. The data on the total activity
performed by Medical Oncology Departments have been
updated to 2013 through information generated by SEOM
[13]. In the case of genetic counselling consultation
activity, estimated based on data on activity in reference
centres, as indicated in Table 1. The optimal time dedi-
cated to each one of the main activities has been updated
considering the increase in complexity of care delivery
and based on the available literature on the subject
[14, 15]. Specifically, regarding time dedication included
in the First White Book of Medical Oncology in Spain,
the time dedicated to the first visit has been increased
from 45 to 60 min, and the second visit has been con-
sidered in a differential way from the rest of subsequent
consultations, estimating optimal dedication at 90 min.
We also considered new activities (not included in pre-
vious studies), which represent a growing proportion of
total medical oncologist’s dedication time, such as tele-
consultations (estimated dedication of 7.5 min/consulta-
tion) and the genetic counselling (90 min estimated for
the first visit and 30 min for subsequent visits). The
optimal dedication time of the medical oncologist for the
first genetic counselling visit was estimated considering
the consultation time and the requirement of later dedi-
cation for the computerization or analysis of genealogical
tree, etc. The optimal times estimated by type of activity
and the sources used for each case are shown in Table 1.
Considering the total activity carried out in Spain in
2013, the optimal dedication times, and the population
requiring health services, we have estimated the number of
working hours of a medical oncologist needed per 100,000
inhabitants to cover the present demand.
For the estimation of the optimal FTE to cover this
demand, the total available time per FTE considered is
37.5 h per week, considering that dedication to healthcare
delivery tasks represents, on average, 72% of the total time
of the workday. The rest of the time would be distributed
between training, research and management activities,
depending on profiles.
Estimation of the number of medical oncologists
needed related to the incidence increase
The estimation of the needs of medical oncologists on the
basis of optimal ratios of new cases/specialist was done
using the incidence projections of the Globocan 2012
Study [4]. In all cases, the needs of specialists were esti-
mated in terms of FTE.
For the estimation of new cases in Medical Oncology
Departments, hematologic cancers were excluded, except-
ing 10% of the new cases of these types of cancer, con-
sidered to be attended at oncology offices.
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Identification of future Medical Oncology trends
and needs
With the aim of collecting the opinion of the Medical
Oncology professionals regarding future trends and needs
of the speciality, an online survey was designed and
addressed to all the medical oncologists, members of
SEOM, with care delivery activity, in the public and/or
private sector. The questionnaire collected opinions related
to future trends and needs of Medical Oncology, through
24 questions distributed in 2 blocks (Block 1 ‘‘Analysis of
trends and needs’’ and Block 2 ‘‘The situation in your
Department’’). The questionnaire used is available for
consultation at http://seom.org/adjunt/Cuestionario_Plan_
de_Futuro_OM.pdf. 176 medical oncologists participated
in the survey, which represents 17.7% of the 993 medical
oncologists who were provided with access to the survey.
Based on conclusions of the online survey, we worked on
the identification of future recommendations through a
face-to-face session with the project’s Advisory Commit-
tee, a work group formed, for this purpose, by members of
SEOM.
Results
The data from the Register of Medical Oncologists, col-
lected within the framework of the project, show that at
present, a total of 1216 medical oncologists (excluding
medical residents) work in care delivery centres, 78% in
centres of the public National Health System with exclusive
dedication; this figure is equivalent to 1141 FTE specialists.
The age pyramid of Spanish medical oncologists
(Fig. 1) shows a young speciality, with predominance of
women (57.6%). This rate is higher in younger frames
(over 70% for oncologists under 35). Only 23.3% of the
current medical oncology workforce is over 50 years old.
The pyramid of professionals working in the private sector
shows a higher rate of men (53.6%) and a higher average
age (34% of medical oncologists in the private sector are
over 50).
The average number of medical oncologists working in
the same department is 6.5. This average is slightly higher
in public centres (7 medical oncologists/departments ver-
sus 4.6 medical oncologists/departments average in the
private sector).
Table 1 Activity by Spanish Medical Oncology Departments in 2013, optimal dedication times and total times by type of activity
Ambulatory care delivery During
hospitalization
On
call
Tum.
commit.
Genetic
counselling
First Sec. Subseq. Telec. DH Stays Cons
ser.
First Subseq
Activity (n8) 127,034a 127,034a 1,533,740a 13,515a 1,231,067a 565,134a 33,149a 33a 57,942a 37,250b 56,105b
Time (min)c 60 90 20 7.5 15 20 30 6.264 h/
y
60 90 30
Total time (h) 127,034 190,551 511,247 1689 307,767 188,378 16,575 206,712 57,942 55,870 28,053
Total work-time
(h) to meet demand
1,691,818
All consultation data refers to consultations in 2013 by medical oncology specialists
First first consultations
Sec second consultations
Subseq subsequent consultations
Telec tele-consultations or consultations not done in person, by oncologists in 2013. Includes consultations resolved with primary care
DH day hospital activity. No. of sessions in day hospital in 2013
Stays Total number of hospital days (stays) in conventional hospitalization units in 2013, considering those in Oncology Departments beds as
well as in other departments in which patients were attended by oncologists
Cons ser consultation services (with other specialists). Number of hospital inter-consultations in 2013
On call ongoing attention. Number of on-call positions located in oncology (excluding residents). To estimate the total hours per year required to
cover ongoing attention, 130.5 h per week (time not covered by a normal work-day), in 33 on-call positions were considered. The time to cover
on-call shifts was not estimated independently, as it has been considered included in the hours estimated to cover the care activities during
conventional work hours
Tum. commit tumours committee No. of Tumour Committee sessions held in 2013
h hours, min minutes, d days, y year
a Activity data in Spanish Medical Oncology Departments corresponding to 2013 [13]
b Estimate based on data on the number of genetic advice consultations in three specialised oncology centres in Catalonia, extrapolating that data
to the population of Spain
c Average dedication time of the Medical Oncology speciality [12, 14, 15]
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Considering the required dedication to different activi-
ties carried out by medical oncologists and the current
volume of activity in the departments, a need of 3621 h of
dedication of medical oncologists per 100,000 inhabitants
(considering Spanish population at 1st January 2013,
according to data from the National Institute for Statistics)
was estimated. Considering the present number of new
cases of cancer (incidence 2013), 822 h would be required
per 100 new cases. Considering the average number of
annual dedication hours per FTE, 2.79 FTE/100,000
inhabitants or a FTE per 158 new cases would be required
to reach these ratios (Table 2).
To reach the ratio of 158 new cases/FTE and depending
on the incidence estimated for 2015, 1352 FTE would be
required. Considering that, according to the register, there
are 1141 FTE, there would be a deficit of 210 FTE (Fig. 2).
Considering that the medical oncology workforce would
maintain an annual average growth of 2.3%, based on
previous available studies [9] and the growth rate in SEOM
membership, the workforce in 2035 will be of 1767 FTE.
Considering the estimates of the number of new cancer
cases included in the Globocan study in our country, 1881
medical oncologists FTE would be required to maintain a
ratio of 158 new cases/FTE in 2035 (Fig. 2). Considering
the estimates of the number of trained specialists in our
country, we would be able to meet this demand in 2035.
Main results of the online survey to medical
oncologists on changes, challenges and future needs
of Medical Oncology
In the opinion of the professionals surveyed, the aspects
that may contribute significantly to improve the quality of
care delivery are the development of a national quality
assessment system and the development of functional units
for specific cancer pathologies. In regard to the relative
needs of cancer research and the introduction of innova-
tions on the basis of their value in the area of oncology, it is
important to note that 76% of the professionals surveyed
request the development of appropriate-for-decision-mak-
ing registers and databases, and 61% report the need for the
development of specific indicators for assessing the quality
of results and managing the incorporation of new evidence-
based therapeutic approaches (Fig. 3).
Fig. 1 Distribution by age and
gender of the Spanish medical
oncologists (Register SEOM
2014)
Table 2 Estimation of the needs of Medical Oncology specialists
based on workloads
Total care delivery
Total time (h) for meeting demand 1,691,818
Hours/105 inhaba 3621.70
Hours/100 new casesb 822.2
No. of FTE needed/105 inhabc 2.79
No. of FTE needed/100 new casesd 0.634
Optimal rate related to incidence 2015 158 new cases/FTE
a To estimate the total hours needed to meet a demand corresponding
to 100,000 inhabitants, total hours required to cover the demand for
oncology services (1,691,818 h) was divided by the population of
Spain as of 1 January 2013 (46.7 million), according to data from the
National Institute for Statistics, and multiplying this ratio by 100,000
b To estimate the total hours needed to meet a demand corresponding
to 100 new cases, incidence projections of the Globocan 2012 Study
[4] were used
c, d Conversion of total hours into full-time equivalents were obtained
considering 37.5 h/week as a FTE. According to data collected and
empirical experience from work group, it was estimated that 72% of
the workday is dedicated to direct patient care. This accounts for
1296 h/year dedicated to patient care per ETC
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In this sense, according to the data collected in this
survey, 85.8% of oncologists do not have data demon-
strating the impact in health outcomes derived from orga-
nizational changes and from the broadening of their service
portfolios, and only 10.9% of professionals report having
participated in studies on health outcomes. In addition,
67.1% feel that their department does not include an
appropriate panel of indicators for the assessment of
quality of care delivery.
The main concerns, challenges and needs of the speciality
reported by the specialists surveyed have been grouped in 5
broad areas: (1) adapting Medical Oncology workforce to
new needs; (2) developing specific care delivery plans
adapted to new profiles and their specific needs; (3) ensuring
the equity and access to quality healthcare delivery; (4)
ensuring earlier diagnosis and (5) advancing towards a more
accurate and comprehensive cancer care delivery. A total of
29 recommendations have been identified (Table 3).
2015 2020 2025 2030 2035 
Difference 
(1) 211 194 180 158 114 
Trained MO 
(FTE)  1,520 1,859 2,188 2,480 
(1) Difference between the number of medical oncologists needed to reach an optimal ratio of 158 new cases /FTE and 
availability of FTE, based on the estimation of an annual increase rate similar to the one experienced in recent years.
1,141
1,276
1,424
1,568
1,767
1,352
1,470
1,604
1,744
1,881
0
200
400
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800
1,000
1,200
1,400
1,600
1,800
2,000
2015 2020 2025 2030 2035
FTE Need of MO for rao 158 new cases /FTEFig. 2 Expected growth of
workforce in baseline scenario
and estimation of FTE needs to
reach ratio of 158 new cases/
FTE
3.4%
21.8%
25.3%
30.5%
32.8%
38.5%
43.7%
47.1%
60.9%
75.9%
Image research support structures
Knowledge transfer training
ICT resources
Pharmacoeconomics training
Biobanks
Facilitate patients’ geographical mobility
Genomic studies infrastructure
Inter-hospital multidisciplinary teams
Specific quality indicators and value of care delivery
Registers and data bases
Fig. 3 Perception of needs regarding the development of priority
research lines and the establishment of innovations based on their
value in Medical Oncology. Results from the online survey ‘‘present
situation, challenges and future needs of MO’’ carried out in 176
Medical Oncologists. The number of valid surveys was 174. Rate of
participants who selected each item among the most relevant 5 is
represented. ICT information and communication technologies
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Table 3 Recommendations included in the Future Plan of Medical Oncology
Areas Recommendations
Area 1
Adapting Medical Oncology workforce to new needs
R1 Adapt the number of MO to the growing needs of cancer care delivery and higher
complexity of patients
R2 Adapt average dedication time per patient, especially in first and second
consultations as well as time dedicated to research
R3 Create a Register of professionals that facilitates ongoing analysis and assessment
of specialists’ needs based on demand changes
R4 Reduce MO’s administrative workload, by strengthening administrative support
resources
R5 Concentrate high complexity care, ensuring optimal resources for its management
R6 Adapt continuous training and Specialised Healthcare Training programmes to the
speciality’s challenges: biomarkers and precision medicine, multidisciplinary
work skills
R7 Strengthen MO contents included in bachelor programmes with a higher
involvement of bachelor MO students
R8 Promote super-specialisation in care delivery teams
Area 2
Developing specific plans of care delivery adapted to
new profiles and their specific needs
R9 Promote the participation of MO in the development of specific plans for long-term
survivors
R10 Promote the participation of MO in the development of specific plans for ongoing
care
R11 Promote the participation of MO in the development of specific plans for care
delivery to elderly and patients with co-morbidities
R12 Improve the coordination MO-Primary Care for the patients’ follow-up
Area 3
Ensuring the equity and access to quality healthcare
delivery
R13 Establish healthcare outcomes assessment and dissemination systems. Creation of
a national quality assessment system
R14 Develop clinical information and treatment plan registers with access for patients
R15 Advance in the definition of agreed protocols/therapy guidelines and promote their
implementation
R16 Define, establish and measure useful indicators for the assessment of care delivery
quality and the impact of innovation incorporation
R17 Facilitate the access of MO to systematic quality assessment tools through actual
outcomes that allow the integration of care delivery, resources management,
economic and health outcome data. Outcome assessment in terms of
effectiveness
R18 Promote participation of Oncology Departments in quality accreditation systems
Area 4
Ensuring earlier diagnosis
R19 Improve coordination MO-Primary Care. Improve resources and training for an
early diagnosis
R20 Ensure the access to early detection strategies with evidence-based usefulness
specially in colorectal, lung breast, cervix and prostate cancer
R21 Promote research in early stages of the disease
Area 5
Advancing towards a more accurate and
comprehensive cancer care delivery
R22 Promote the creation of multidisciplinary teams for all kinds of cancers
R23 Promote the creation of inter-hospital joint services (care delivery, training and
research in collaboration)
R24 Promote the creation of centres based on the philosophy of Comprehensive Cancer
Centre, which integrate multidisciplinary care delivery, training and research in
cancer
R25 Increase the use of ICT for promoting inter/multidisciplinary work
R26 Promote research in biomarkers, immunotherapy and combined therapies
R27 Promote network research for increasing its scope
R28 Facilitate the inclusion of patients in clinical trials through the use of ICT
R29 Promote the creation of patient registers and ensure optimal exploitation of
electronic medical history data
MO medical oncology or medical oncologists, ICT information and communication technologies
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Area 1: adapting the medical oncology workforce to new
needs
The optimal ratios for resources planning must be based on
workload. This load must be estimated considering the
appropriate dedication time to the different types of
activities carried out by medical oncologists (especially to
second consultations and consultations with patients
included in clinical trials). This adjustment in dedication
time must take into account changes in the patient profiles,
the increase in prevalence and complexity, and the devel-
opment of new services and activities, such as the inter-
pretation of diagnostic tests. The development of a Register
of Professionals that allows ongoing analysis and fore-
casting of the needs of specialists is another recommen-
dation in this area.
Area 2: developing specific care delivery plans adapted
to new profiles and their specific needs
The main recommendations in this area are to define and
organise the participation of medical oncologists in the
application of the specific plans for long-term survivors,
palliative care and the development of specific plans for
special populations (elderly and patients with co-morbidi-
ties). Specifically, care delivery to a growing number of
long-term cancer survivors is considered one of the main
challenges for the speciality. One of the improvement areas
reported is the development of more effective coordination
strategies with Primary Care, including a coordinated
treatment plan that meets the needs of this group of
patients, to allow more effective follow up and avoid
duplication of tests.
Area 3: ensuring equality and access to quality healthcare
delivery
Equal access to quality health services must be grounded
on an adequate measurement of health outcomes obtained
by the system, with quality indicators that allow the com-
parison between services and systems to determine which
actions and structure, organizational or treatment changes
are contributing the most to the system. Indeed, the cre-
ation of a national system of care delivery quality assess-
ment would be desirable. This would allow more
coordinated work, as well as the generalization of systems
for the assessment and dissemination of health outcomes.
The contribution of Medical Oncologists to the gener-
ation of quality Registers of Patients and Clinical Infor-
mation, as well as the access to tools for the systematic
review of their activity, are considered to be essential for
the development of studies that ensure the establishment of
more effective strategies. It is also necessary to advance in
the definition of accepted protocols and establish the
resources required to facilitate their implementation.
Area 4: ensuring early diagnosis
The main recommendations in this area include ensuring
the access by population to appropriate early diagnosis
strategies, especially in breast, lung and colo-rectal cancer,
the establishment of tools for the early detection, and
referral from Primary Care and the promotion of research
on early stages of the disease.
Area 5: advancing towards more accurate
and comprehensive cancer care delivery
Promotion of research on biomarkers, immunotherapy and
combined therapies, and boosting the creation of centres
based on the philosophy of Comprehensive Cancer Centre,
integrating cancer multi-disciplinary care delivery, training
and research, are considered essential lines of work to
advance in a more and more accurate and comprehensive
approach of cancer.
Finally, universal access must be granted, within
appropriate times, to the determination of biomarkers of
quality and clinical evidence-based usefulness. We, there-
fore, recommend the creation of a national biomarker
platform associated with a specific register.
Discussion
Register and future needs of medical oncologists
SEOM decided to promote the elaboration of the Future
Plan for Medical Oncology as a means of establishing the
speciality’s strategic lines of development in the coming
years and address future potential workforce shortages,
with the participation and opinion of a large number of the
Society’s members.
Both the American Society of Clinical Oncology
(ASCO) and the European Society for Medical Oncology
(ESMO) have approached this subject through similar
studies aimed to identify differences between the actual
needs of oncologists with regard to the increase of the
Departments’ needs and to the previsions on the number of
available professionals, in the basis of the expected
workforce growth. According to a study published by
ASCO in 2015, it was estimated that demand for medical
oncology services would increase by 42% in the USA by
2025. Nevertheless, the expected growth of the oncology
and haematology workforce is estimated at 28% for the
same period, which means a foreseeable deficit of 1487
FTE oncology/haematology specialists in 2015 [16].
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Different studies conducted in the last few years in Aus-
tralia, Japan, Latin America, France and Belgium, also
report an expected shortfall of specialists in the area of
oncology within the next years [10]. According to this
study published in 2014, the ratio of cancer cases per FTE
in 2008 in European countries ranged from 113 in Hungry
and 1067 in the United Kingdom, and these ratios are
expected to decrease in the coming years in most of the
countries. The study reported, however, as its main limi-
tation, the lack of information on professionals in several
countries, including Spain [10].
Studies from the University of Las Palmas de Gran
Canaria (Spain) on the supply and demand for medical
oncologists in Spain have been the main source of infor-
mation on resource planning for different specialities [9].
Several scientific associations have promoted studies on
the needs of different specialists [17, 18], for instance, the
Spanish Association of Cardiology reports in its last study
the existence of an imbalance of around 14% between the
number of active cardiologists and the number needed [17].
Due to the lack of updated data, and in expectation of
the results from the unified Register of Professionals, we
decided to prepare our own register, with the aim of
determining the current situation of Medical Oncology
Departments related to the medical oncology workforce in
Spain. It was also considered necessary to estimate the
optimal ratios based on the increase and complexity of the
current demand, and to compare the data obtained with
published optimum ratios.
According to the data from published international
standards, the optimal range of new cases/FTE is estimated
to be between 150 and 180 [19]. In our study, the data from
the Register of Medical Oncologists show a deficit of 211
FTE to achieve optimal ratios, estimated at 158 new cases/
FTE, which means an imbalance of 18%. Our study also
shows a lower average size of the Departments’ workforce,
which is around 6.5 medical oncologists/Department
compared to data from other countries such as USA where
the average is 15 specialists/Department [16]. Our study
also reports the concern regarding the dispersion and
breakup of Departments experienced in recent years. This
fact has been identified as an element that hinders the
concentration of a sufficient number of cases to ensure
equality in healthcare delivery quality.
The ageing of the population will foreseeably result in
an increase in demand for oncology services. In 2012, 60%
of the new cases of cancer in Spain corresponded to
patients 65 years of age or older. This rate is expected to
increase to 67% in 2035 [4]. Despite the expected decrease
in the Spanish population within the next 10 years, the
ageing trend will be maintained, and the number of people
aged 65 or over is estimated at more than 12.5 million by
2025, an increase of 56% from 2012 [20]. Due to the
difficulty of estimating activity figures corresponding
specifically to the older population, we opted to use ratios
in comparison with the general population, allowing that
this aspect may be generating an underestimation of the
demand in the coming years. Also, the incidence projec-
tions, used to estimate future needs, include the foreseeable
ageing of the population in Spain in the year to come.
To attain the optimal number of 1881 FTE by 2035, the
medical oncology workforce should present an annual
average growth of 2.5%. According to a study in 12
European countries, the average workforce growth was
5.3% (balancing in a range between 1.8 and 8.7%) [10], so
that the estimated growth rates for Spain would be within
this range. The difference between the number of profes-
sionals trained in Medical Oncology and the expected
retirements, would make it possible to cover this workforce
growth, if the current number of internship positions
remain constant, as it is estimated that 2480 medical
oncologists would be available by 2035 (Fig. 2).
The main limitation identified in the study is the pos-
sible margin of error derived from the estimates of the
register due to the lack of complete data from all regions,
and the forecasts regarding the estimation of the number of
future cancer cases. Although the estimated needs based on
the forecast of the number of cases is considered a valid
model, the estimation of prevalence projections may be a
more precise model for estimating the actual workload.
In regard to the updating of workloads, the lack of
information on the rate of consultations with patients
included in clinical trials, or the time dedicated to home
care, is also a limitation. Despite the estimated mainte-
nance of 72% of time dedicated to care delivery, based on
the need for increased involvement by medical oncologists
in research, training and management, we recommend that
this rate be revised downward to allow time to be allocated
to these tasks.
In the coming years, there may be an increase in
absences due to common illness, and the workforce needs
may increase due to burn-out syndrome. These two factors
would offset the expected reduction in maternity leave
considered in the model. In this sense, a report prepared by
ASCO in 2012 indicated that 44.7% of oncologists/
haematologists in the US said that they suffered burn-out,
especially in profiles with greater dedication to care
activity. Close to 27% of oncologists said that they would
like to reduce their work hours over the next 12 months,
34% would consider leaving their current job, and 28%
planned to retire before the age of 65.
In a scenario of regulatory changes related to require-
ments for ordinary, partial, and early retirement, their dif-
ferent application at the regional healthcare services level
and the diverse models for the hiring of medical profes-
sionals applied in recent years in Spain, an average
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retirement age of 65 was adopted. Even admitting that this
estimate could cause a potential underestimation of the
number of professionals in active service in the coming
years, the possible impact of other factors, such as burn-out
or possible budgetary limitations, which could lead to an
increase in early retirement, must be taken into
consideration.
Concerns, challenges and needs of Medical
Oncology
The low participation in studies on health outcomes was
one of the most remarkable conclusion of the survey (only
10.9% of those surveyed reported that they had participated
in studies of this kind, despite the acknowledgement of
their importance in the planning and incorporation of
innovations to the National Health System). Although the
available information is limited, the main programmes of
comprehensive oncology applied in different countries
acknowledge the need to generate evidence that proves its
increased effectiveness in comparison with traditional
models of cancer approaches. It is important to carry out a
continuous assessment of key indicators related to control
of symptoms, adherence to treatment protocols, quality of
life, individual outcomes, prevention, rehabilitation, eco-
nomic impact in services, and considerations regarding the
impact on the health system as a whole [21].
Conclusions
The estimation of the current workload of medical oncol-
ogists based on the current service demand and the required
dedication to the main activities made it possible to esti-
mate that an optimal ratio of 158 new cases per FTE should
be reached. At present 1352 FTE would be required to
reach this optimal ratio, versus the 1141 FTE available,
which means a deficit of 211 FTE. 1881 FTE would be
required to reach the optimal ratio in 2035, which would
involve an average annual workforce growth of 2.5%.
Based on the needs and challenges identified by medical
oncologists, SEOM would like to highlight the need to
progress towards the establishment of actions that: (1)
move forward in regard to improvement of healthcare
delivery, equal access to care delivery, and increased
effectiveness by promoting health outcomes assessment,
(2) build more accurate quality indicators, useful for
decision-making in the area of medical oncology and (3)
ensure that the size of the medical oncology workforce will
be appropriate in size to address future demands.
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